cytosine has been researched along with Neutropenia in 6 studies
Neutropenia: A decrease in the number of NEUTROPHILS found in the blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The objective of this study was to develop a mechanism-based population pharmacokinetic/pharmacodynamic (PK/PD) model in describing troxacitabine-induced neutropenia in patients with cancer." | 7.77 | Mechanism-based pharmacokinetic/pharmacodynamic model for troxacitabine-induced neutropenia in cancer patients. ( Beeram, M; Lin, CC; Ng, CM; Patnaik, A; Takimoto, CH, 2011) |
| "The objective of this study was to develop a mechanism-based population pharmacokinetic/pharmacodynamic (PK/PD) model in describing troxacitabine-induced neutropenia in patients with cancer." | 3.77 | Mechanism-based pharmacokinetic/pharmacodynamic model for troxacitabine-induced neutropenia in cancer patients. ( Beeram, M; Lin, CC; Ng, CM; Patnaik, A; Takimoto, CH, 2011) |
| " To confirm the safety and tolerability of dosing schedules, after 20 patients had been treated in a group we enrolled an expanded cohort of 20-25 patients to that group if at least four patients had achieved complete remission or complete remission with incomplete blood count recovery, and if the 30 day death rate was 20% or less." | 2.77 | Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study. ( Arellano, M; Chiao, J; Claxton, D; Coutre, S; Faderl, S; Garcia-Manero, G; Goldberg, SL; Jabbour, E; Kantarjian, H; Luger, S; Maness, L; Plunkett, W; Schiller, G; Seiter, K; Stock, W; Strickland, SA; Venugopal, P; Wetzler, M, 2012) |
| "To assess the feasibility of administering troxacitabine, an L-nucleoside analog that is not a substrate for deoxycytidine deaminase, in combination with cisplatin, to identify pharmacokinetic interactions, and to seek preliminary evidence of antitumor activity." | 2.74 | Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies. ( Beeram, M; De Bono, JS; Denis, LJ; Geyer, CE; Hao, D; Jolivet, J; Lin, CC; Ng, CM; Patnaik, A; Rha, SY; Rowinsky, EK; Takimoto, CH; Tolcher, AW, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lin, CC | 2 |
| Beeram, M | 2 |
| Rowinsky, EK | 1 |
| Takimoto, CH | 2 |
| Ng, CM | 2 |
| Geyer, CE | 1 |
| Denis, LJ | 1 |
| De Bono, JS | 1 |
| Hao, D | 1 |
| Tolcher, AW | 1 |
| Rha, SY | 1 |
| Jolivet, J | 1 |
| Patnaik, A | 2 |
| Tjon Pian Gi, RE | 2 |
| Dietz, A | 2 |
| Djukic, V | 1 |
| Eckel, HE | 1 |
| Friedrich, G | 2 |
| Golusinski, W | 2 |
| Hantzakos, A | 2 |
| Lawson, G | 2 |
| Remacle, M | 2 |
| Rihkanen, H | 1 |
| Dikkers, FG | 2 |
| Kantarjian, H | 1 |
| Faderl, S | 1 |
| Garcia-Manero, G | 1 |
| Luger, S | 1 |
| Venugopal, P | 1 |
| Maness, L | 1 |
| Wetzler, M | 1 |
| Coutre, S | 1 |
| Stock, W | 1 |
| Claxton, D | 1 |
| Goldberg, SL | 1 |
| Arellano, M | 1 |
| Strickland, SA | 1 |
| Seiter, K | 1 |
| Schiller, G | 1 |
| Jabbour, E | 1 |
| Chiao, J | 1 |
| Plunkett, W | 1 |
| Ilmarinen, T | 1 |
| van den Heuvel, ER | 1 |
| Aaltonen, LM | 1 |
| Andersen, J | 1 |
| Brunings, JW | 1 |
| Chirila, M | 1 |
| Ferran Vilà, F | 1 |
| de Gier, HH | 1 |
| Graupp, M | 1 |
| Horcasitas, R | 1 |
| Jackowska, J | 1 |
| Koelmel, JC | 1 |
| Lindner, F | 1 |
| Sittel, C | 1 |
| Weichbold, V | 1 |
| Wierzbicka, M | 1 |
| Ong, ST | 1 |
| Kueh, YK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Phase 2 Study of Oral Sapacitabine in Elderly Patients With Acute Myeloid Leukemia Previously Untreated or in First Relapse, or Previously Treated Myelodysplastic Syndromes[NCT00590187] | Phase 2 | 408 participants (Actual) | Interventional | 2007-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for cytosine and Neutropenia
| Article | Year |
|---|---|
Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytosine; Dioxolanes; Dose-R | 2009 |
Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anemia; Arabinonucleosides; Cytosine; Disease-Free Su | 2012 |
4 other studies available for cytosine and Neutropenia
| Article | Year |
|---|---|
Mechanism-based pharmacokinetic/pharmacodynamic model for troxacitabine-induced neutropenia in cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytos | 2011 |
Treatment of recurrent respiratory papillomatosis and adverse reactions following off-label use of cidofovir (Vistide®).
Topics: Adverse Drug Reaction Reporting Systems; Antiviral Agents; Cidofovir; Cytosine; Injections, Intrales | 2012 |
Safety of intralesional cidofovir in patients with recurrent respiratory papillomatosis: an international retrospective study on 635 RRP patients.
Topics: Antiviral Agents; Cidofovir; Combined Modality Therapy; Cytosine; Female; Head and Neck Neoplasms; H | 2013 |
Hepatic candidiasis: persistent pyrexia in a patient with acute myeloid leukaemia after recovery from consolidation therapy-induced neutropenia.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Candidiasis; Cytosine; Eto | 1993 |